Maiweibio (688062.SH): has submitted an application for H-share issuance and listing, and has published the application documents.
Maiwei Biology (688062.SH) announced that the company has submitted to the Hong Kong Stock Exchange on January 6, 2025...
Maiwei Biotechnology (688062.SH) announced that the company submitted an application to the Hong Kong Stock Exchange on January 6, 2025 for the issuance of H shares and listing on the main board of the Hong Kong Stock Exchange. The application materials for this issuance were also published on the exchange's website on the same day.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
